Table 1. results from phase 1, phase 2 and phase 3 studies investigating the efficacy of osimertinib.

Study (ref)	Treatment	Number of patients	ORR (%), OR (95% CI)	PFS (months), HR (95% CI)
AURA 1 (phase 1) (7)	Osimertinib	127 T790M+	61 (52–70)	9.6 (8.3–NR)
AURA2 (phase 2) (8)	Osimertinib	210 T790M+	70 (64–77)	9.9 (8.5–12.3)
AURA 3 (phase 3) (10)	Osimertinib vs. platinum-pemetrexed	419 T790M+	71 vs. 31 OR 5.39, (3.47–8.48) P<0.001	10.1 vs. 4.4 HR 0.30, (0.23–0.41) P<0.001
Kato et al. (11)	Osimertinib	31 T790M+	53.3	5.6 (3.6–14.8)

ORR, objective response rate; OR, odds ratio; PFS, progression free survival; HR, hazard ratio.